Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma (NHL)
Multiple Myeloma
Waldenstrom's Macroglobulinemia (WM)
Other B-cell NHL Subtypes, Including WM
T-cell NHL

Interventions

DRUG: CB-839
DRUG: CB-839 and low dose dexamethasone
DRUG: CB-839, pomalidomide, and low dose dexamethasone

Sponsor

Calithera Biosciences, Inc